Active — Not RecruitingNot Applicable

Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)

United States31 participantsStarted 2022-06-07

Plain-language summary

The main goal of this study is to improve dysexecutive symptoms (e.g., sustained attention, processing speed) in patients exhibiting post-acute sequelae of COVID-19 (PASC) through home-based transcranial direct current stimulation (tDCS), a noninvasive method that uses low intensity electric currents delivered to the brain through stimulation electrodes on the scalp.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Ability to provide informed consent * A diagnosis of PASC as indicated by past COVID-19 infection, and persistent symptoms, including 'brain fog', confusion, short-term memory deficits, trouble concentrating, delirium, difficulties in multitasking. Exclusion Criteria: * History of epilepsy * Metallic implants in the head and neck, * Brain stimulators * Pacemakers * Pregnancy * Active substance dependence (except for tobacco) * Premorbid major neurological illness * Severe mental illness (e.g., bipolar disorder, schizophrenia) * Attention Deficit Hyperactivity Disorder

What they're measuring

Inhibitory Control

Timeframe: Baseline

Inhibitory Control

Timeframe: Posttreatment (1 month follow-up)

Processing Speed

Timeframe: Baseline

Processing Speed

Timeframe: Posttreatment (1 month follow-up)

EEG P300 Event-related Potential

Timeframe: Baseline

EEG P300 Event-related Potential

Timeframe: Posttreatment (1 month follow-up)

Trial details

NCT IDNCT05092516

SponsorMassachusetts General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-03-13

Results submitted2026-03-12

View on ClinicalTrials.gov More Dysexecutive Syndrome trials